MX2022002075A - Usos terapeuticos de anticuerpos anti-variable delta 1 de tcr. - Google Patents
Usos terapeuticos de anticuerpos anti-variable delta 1 de tcr.Info
- Publication number
- MX2022002075A MX2022002075A MX2022002075A MX2022002075A MX2022002075A MX 2022002075 A MX2022002075 A MX 2022002075A MX 2022002075 A MX2022002075 A MX 2022002075A MX 2022002075 A MX2022002075 A MX 2022002075A MX 2022002075 A MX2022002075 A MX 2022002075A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- therapeutic uses
- tcr delta
- delta variable
- variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911799.3A GB201911799D0 (en) | 2019-08-16 | 2019-08-16 | Novel Antibodies |
| GBGB2010760.3A GB202010760D0 (en) | 2020-07-13 | 2020-07-13 | Novel antibodies |
| PCT/GB2020/051959 WO2021032963A1 (en) | 2019-08-16 | 2020-08-14 | Therapeutic uses of anti-tcr delta variable 1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002075A true MX2022002075A (es) | 2022-03-17 |
Family
ID=72148174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002075A MX2022002075A (es) | 2019-08-16 | 2020-08-14 | Usos terapeuticos de anticuerpos anti-variable delta 1 de tcr. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220403025A1 (enExample) |
| EP (2) | EP4013505A1 (enExample) |
| JP (4) | JP2022545196A (enExample) |
| KR (2) | KR20220084019A (enExample) |
| CN (2) | CN114222585A (enExample) |
| AU (4) | AU2020332878B2 (enExample) |
| BR (1) | BR112022002837A2 (enExample) |
| CA (2) | CA3145517A1 (enExample) |
| CL (2) | CL2022000368A1 (enExample) |
| CO (1) | CO2022002001A2 (enExample) |
| IL (1) | IL290537A (enExample) |
| MX (1) | MX2022002075A (enExample) |
| WO (2) | WO2021032960A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| MX386714B (es) | 2015-01-27 | 2025-03-11 | Lava Therapeutics N V | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
| WO2019147735A1 (en) | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用ＣＤ１ｄ免疫グロブリン |
| CA3127103A1 (en) | 2019-01-23 | 2020-07-30 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| JP2022545196A (ja) * | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| GB202002581D0 (en) * | 2020-02-24 | 2020-04-08 | Gammadelta Therapeutics Ltd | Novel antibodies |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| ES2943063T5 (en) * | 2020-08-14 | 2026-05-05 | Gammadelta Therapeutics Ltd | Multispecific anti-tcr delta variable 1 antibodies |
| MX2023009544A (es) | 2021-02-17 | 2023-11-28 | Gammadelta Therapeutics Ltd | Anticuerpos anti-variable delta 1 de tcr multiespecíficos. |
| KR20230160253A (ko) | 2021-02-17 | 2023-11-23 | 감마델타 테라퓨틱스 엘티디 | 항-tcr 델타 가변 1 항체 |
| EP4147716A1 (en) * | 2021-09-10 | 2023-03-15 | Samatva Research Corporation | Anti-virus moiety immobilised in a matrix |
| CA3208653A1 (en) | 2022-02-17 | 2022-08-25 | Mihriban Tuna | Multispecific anti-tcr delta variable 1 antibodies |
| EP4688851A1 (en) | 2023-03-27 | 2026-02-11 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| CN121752599A (zh) * | 2023-08-31 | 2026-03-27 | 南京传奇生物科技有限公司 | 抗γδTCR抗体及其用途 |
| WO2026087747A1 (en) | 2024-10-24 | 2026-04-30 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof |
| WO2026087748A1 (en) | 2024-10-24 | 2026-04-30 | Avidicure Ip B.V. | Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof |
| US20260152558A1 (en) | 2024-11-27 | 2026-06-04 | Gammadelta Therapeutics Ltd | Multispecific anti-tcr delta variable 1 antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100591761C (zh) * | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| CN102295702B (zh) * | 2011-08-26 | 2014-01-29 | 中国科学院微生物研究所 | 一种针对t细胞受体可变区特异性单抗的制备方法 |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| RU2756247C2 (ru) * | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| JP6799895B2 (ja) | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． | ＴＣＲγδ＋Ｔ細胞の生産方法 |
| CN108473958A (zh) | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| PE20190115A1 (es) * | 2016-04-15 | 2019-01-16 | Immunext Inc | Anticuerpos vista antihumanos y su uso |
| CN118421557A (zh) | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| US10546518B2 (en) | 2017-05-15 | 2020-01-28 | Google Llc | Near-eye display with extended effective eyebox via eye tracking |
| WO2019147735A1 (en) * | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| JP7686571B2 (ja) * | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞媒介性免疫を調節するための材料及び方法 |
| JP2022545196A (ja) * | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
-
2020
- 2020-08-14 JP JP2022509647A patent/JP2022545196A/ja active Pending
- 2020-08-14 CA CA3145517A patent/CA3145517A1/en active Pending
- 2020-08-14 BR BR112022002837A patent/BR112022002837A2/pt unknown
- 2020-08-14 KR KR1020227008859A patent/KR20220084019A/ko active Pending
- 2020-08-14 EP EP20758308.9A patent/EP4013505A1/en active Pending
- 2020-08-14 US US17/633,439 patent/US20220403025A1/en active Pending
- 2020-08-14 MX MX2022002075A patent/MX2022002075A/es unknown
- 2020-08-14 EP EP20758305.5A patent/EP4013504A1/en active Pending
- 2020-08-14 WO PCT/GB2020/051955 patent/WO2021032960A1/en not_active Ceased
- 2020-08-14 AU AU2020332878A patent/AU2020332878B2/en active Active
- 2020-08-14 WO PCT/GB2020/051959 patent/WO2021032963A1/en not_active Ceased
- 2020-08-14 CN CN202080057206.1A patent/CN114222585A/zh active Pending
- 2020-08-14 KR KR1020227008860A patent/KR20220084020A/ko active Pending
- 2020-08-14 JP JP2022509648A patent/JP2022544683A/ja active Pending
- 2020-08-14 CA CA3145523A patent/CA3145523A1/en active Pending
- 2020-08-14 CN CN202080065477.1A patent/CN114514245A/zh active Pending
- 2020-08-14 AU AU2020333406A patent/AU2020333406B2/en active Active
-
2022
- 2022-02-10 IL IL290537A patent/IL290537A/en unknown
- 2022-02-15 CL CL2022000368A patent/CL2022000368A1/es unknown
- 2022-02-24 CO CONC2022/0002001A patent/CO2022002001A2/es unknown
-
2024
- 2024-07-25 CL CL2024002250A patent/CL2024002250A1/es unknown
-
2025
- 2025-07-04 JP JP2025113769A patent/JP2025160218A/ja active Pending
- 2025-09-12 JP JP2025152149A patent/JP2026009903A/ja active Pending
-
2026
- 2026-07-09 AU AU2026205443A patent/AU2026205443A1/en active Pending
- 2026-07-10 AU AU2026205504A patent/AU2026205504A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022002837A2 (pt) | 2022-05-10 |
| CL2024002250A1 (es) | 2024-11-29 |
| WO2021032963A1 (en) | 2021-02-25 |
| CN114514245A (zh) | 2022-05-17 |
| EP4013505A1 (en) | 2022-06-22 |
| AU2020332878B2 (en) | 2026-07-30 |
| AU2026205504A1 (en) | 2026-07-30 |
| IL290537A (en) | 2022-04-01 |
| WO2021032960A1 (en) | 2021-02-25 |
| CN114222585A (zh) | 2022-03-22 |
| AU2020332878A1 (en) | 2022-01-27 |
| AU2020333406B2 (en) | 2026-07-30 |
| KR20220084019A (ko) | 2022-06-21 |
| AU2026205443A1 (en) | 2026-08-06 |
| KR20220084020A (ko) | 2022-06-21 |
| CO2022002001A2 (es) | 2022-04-08 |
| EP4013504A1 (en) | 2022-06-22 |
| AU2020333406A1 (en) | 2022-01-27 |
| US20220403025A1 (en) | 2022-12-22 |
| JP2026009903A (ja) | 2026-01-21 |
| CA3145517A1 (en) | 2021-02-25 |
| CA3145523A1 (en) | 2021-02-25 |
| JP2022545196A (ja) | 2022-10-26 |
| JP2022544683A (ja) | 2022-10-20 |
| CL2022000368A1 (es) | 2022-09-30 |
| JP2025160218A (ja) | 2025-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022002001A2 (es) | Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr | |
| CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| MX2021015518A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| CY1123229T1 (el) | Χρηση των κανναβινοειδων στη θεραπεια των ατονικων κρισεων στο συνδρομο lennox-gastaut | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| CL2025003689A1 (es) | Anticuerpos de cadena pesada que se unen al psma. | |
| CR20190550A (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| MX2022003212A (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso. | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| MX2020009861A (es) | Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos. | |
| CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| MX2017014136A (es) | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. | |
| CL2021002389A1 (es) | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296) | |
| MX2017009904A (es) | Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3). | |
| MX392789B (es) | Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias | |
| DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
| MX2020010653A (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso. | |
| CL2025002872A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| CO2021014260A2 (es) | Formas sólidas de un inhibidor de glyt1 | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| AR105541A1 (es) | ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh | |
| MX2021003119A (es) | Anticuerpos anti-klrg1. | |
| UY38883A (es) | Anticuerpos contra el factor de las células madre, y métodos de uso de ellas | |
| CL2021002866A1 (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. |